ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 85.16 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 69.97K shares, a 75.38% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 15.19K shares, a 71.25% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 11.50K shares, a 83.48% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 58.48K shares, a 84.45% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 406.97K shares, a 46.83% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 765.39K shares, a 1.08% increase from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 757.19K shares, a 21.96% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 620.86K shares, a 1447.67% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 69.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 85.16K shares 10-Q · filed 2026-08-04 | 96.65K shares derived: sum of 3 quarters · filed 2026-08-04 | 155.13K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 15.19K shares 10-Q · filed 2026-05-05 | 26.69K shares derived: sum of 2 quarters · filed 2026-05-05 | 85.17K shares derived: sum of 3 quarters · filed 2026-05-05 | 369.33K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 11.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 69.97K shares derived: sum of 2 quarters · filed 2026-02-26 | 354.14K shares derived: sum of 3 quarters · filed 2026-02-26 | 406.97K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 58.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 342.64K shares derived: sum of 2 quarters · filed 2025-11-05 | 395.48K shares 10-Q · filed 2025-11-05 | 465.07K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 284.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 337.00K shares 10-Q · filed 2025-08-05 | 406.59K shares derived: sum of 3 quarters · filed 2025-08-05 | 782.76K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 52.84K shares 10-Q · filed 2025-05-01 | 122.43K shares derived: sum of 2 quarters · filed 2025-05-01 | 498.60K shares derived: sum of 3 quarters · filed 2025-05-01 | 750.28K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 69.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 445.76K shares derived: sum of 2 quarters · filed 2025-03-03 | 697.44K shares derived: sum of 3 quarters · filed 2025-03-03 | 765.39K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 376.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 627.84K shares derived: sum of 2 quarters · filed 2024-11-07 | 695.80K shares 10-Q · filed 2024-11-07 | 1.11M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 251.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 319.63K shares 10-Q · filed 2024-08-01 | 736.77K shares derived: sum of 3 quarters · filed 2024-08-01 | 923.85K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 67.95K shares 10-Q · filed 2024-05-07 | 485.08K shares derived: sum of 2 quarters · filed 2024-05-07 | 672.17K shares derived: sum of 3 quarters · filed 2024-05-07 | 744.52K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 417.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 604.22K shares derived: sum of 2 quarters · filed 2024-02-29 | 676.57K shares derived: sum of 3 quarters · filed 2024-02-29 | 757.19K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 187.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 259.44K shares derived: sum of 2 quarters · filed 2023-11-09 | 340.06K shares 10-Q · filed 2023-11-09 | 464.46K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 72.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 152.97K shares 10-Q · filed 2023-08-02 | 277.38K shares derived: sum of 3 quarters · filed 2023-08-02 | 406.10K shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 80.62K shares 10-Q · filed 2023-05-03 | 205.03K shares derived: sum of 2 quarters · filed 2023-05-03 | 333.75K shares derived: sum of 3 quarters · filed 2023-05-03 | 651.41K shares derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | 124.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | 253.13K shares derived: sum of 2 quarters · filed 2023-02-14 | 570.79K shares derived: sum of 3 quarters · filed 2023-02-14 | 620.86K shares 10-K · filed 2023-02-14 |
| 2022-09-30 | 128.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 446.38K shares derived: sum of 2 quarters · filed 2022-11-03 | 496.46K shares 10-Q · filed 2022-11-03 | 515.12K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 317.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 367.74K shares 10-Q · filed 2022-08-03 | 386.40K shares derived: sum of 3 quarters · filed 2022-08-03 | 388.23K shares derived: sum of 4 quarters · filed 2022-08-03 |
| 2022-03-31 | 50.07K shares 10-Q · filed 2022-05-04 | 68.74K shares derived: sum of 2 quarters · filed 2022-05-04 | 70.56K shares derived: sum of 3 quarters · filed 2022-05-04 | 80.14K shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 18.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 20.49K shares derived: sum of 2 quarters · filed 2022-02-15 | 30.07K shares derived: sum of 3 quarters · filed 2022-02-15 | 40.12K shares 10-K · filed 2022-02-15 |
| 2021-09-30 | 1.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 11.40K shares derived: sum of 2 quarters · filed 2021-11-03 | 21.45K shares 10-Q · filed 2021-11-03 | 21.45K shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 9.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 19.63K shares 10-Q · filed 2021-08-04 | 19.63K shares derived: sum of 3 quarters · filed 2021-08-04 | 24.63K shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 10.05K shares 10-Q · filed 2021-05-05 | 10.05K shares derived: sum of 2 quarters · filed 2021-05-05 | 15.05K shares derived: sum of 3 quarters · filed 2021-05-05 | |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | 5.00K shares derived: sum of 2 quarters · filed 2021-02-24 | 15.00K shares 10-K · filed 2021-02-24 | |
| 2020-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 15.00K shares 10-Q · filed 2020-11-10 | ||
| 2020-06-30 | 10.00K shares 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |